SGLT2 inhibitors safe for use in type 1 diabetes say researchers
Sodium-glucose cotransporter 2 (SGLT2) inhibitor could benefit people with type 1 diabetes, a US study has suggested.
The drug is currently approved for the management of type 2 diabetes but not available for use alongside insulin in the treatment of type 1 diabetes.
Researchers from Wayne State University in the US reviewed the available evidence of the effects of SGLT2 inhibitors on HbA1c, body weight, and total daily insulin dose, as well as their safety profile in patients with type 1 diabetes.
The study published in Diabetes Research Clinical Practice concluded: “The current study lends supports for the development of SGLT2 inhibitors in combination with insulin as a treatment option for patients with type 1 diabetes.”
The investigation identified four randomized controlled trials (RCTs) through a systematic search of PubMed, Embase, Web of Science, Scopus and Cochrane library databases through August 2017.
The results suggested: “Relative to placebo, therapy with SGLT2 inhibitors led to significant reductions in HbA1c (WMD 0.39; 95 per cent CI 0.27, 0.51), body weight (WMD 2.76; 95 per cent CI 1.11, 4.40), and total daily insulin dose (WMD 5.03; 95 per cent CI 1.83, 8.23). In addition, there was no significant difference in the rate of adverse events.”
To view the study, click here.